<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Interv Aging</journal-id><journal-id journal-id-type="iso-abbrev">Clin Interv Aging</journal-id><journal-id journal-id-type="publisher-id">Clinical Interventions in Aging</journal-id><journal-title-group><journal-title>Clinical Interventions in Aging</journal-title></journal-title-group><issn pub-type="ppub">1176-9092</issn><issn pub-type="epub">1178-1998</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25143719</article-id><article-id pub-id-type="pmc">4136953</article-id><article-id pub-id-type="doi">10.2147/CIA.S61760</article-id><article-id pub-id-type="publisher-id">cia-9-1327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Cognitive effects of testosterone and finasteride administration in older hypogonadal men</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Borst</surname><given-names>Stephen E</given-names></name><xref ref-type="aff" rid="af1-cia-9-1327">1</xref><xref ref-type="corresp" rid="c1-cia-9-1327"/></contrib><contrib contrib-type="author"><name><surname>Yarrow</surname><given-names>Joshua F</given-names></name><xref ref-type="aff" rid="af2-cia-9-1327">2</xref></contrib><contrib contrib-type="author"><name><surname>Fernandez</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="af1-cia-9-1327">1</xref></contrib><contrib contrib-type="author"><name><surname>Conover</surname><given-names>Christine F</given-names></name><xref ref-type="aff" rid="af2-cia-9-1327">2</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Fan</given-names></name><xref ref-type="aff" rid="af2-cia-9-1327">2</xref></contrib><contrib contrib-type="author"><name><surname>Meuleman</surname><given-names>John R</given-names></name><xref ref-type="aff" rid="af1-cia-9-1327">1</xref></contrib><contrib contrib-type="author"><name><surname>Morrow</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="af3-cia-9-1327">3</xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Baiming</given-names></name><xref ref-type="aff" rid="af4-cia-9-1327">4</xref></contrib><contrib contrib-type="author"><name><surname>Shuster</surname><given-names>Jonathan J</given-names></name><xref ref-type="aff" rid="af5-cia-9-1327">5</xref></contrib></contrib-group><aff id="af1-cia-9-1327"><label>1</label>Geriatric Research, Education and Clinical Center, Gainesville Florida</aff><aff id="af2-cia-9-1327"><label>2</label>Research Service, Malcom Randall VA Medical Center, Gainesville Florida</aff><aff id="af3-cia-9-1327"><label>3</label>Pharmacy Service, Malcom Randall VA Medical Center, Gainesville Florida</aff><aff id="af4-cia-9-1327"><label>4</label>Department of Biostatistics, University of Florida, Gainesville, FL, USA</aff><aff id="af5-cia-9-1327"><label>5</label>Department of Health Outcomes and Policy, University of Florida, Gainesville, FL, USA</aff><author-notes><corresp id="c1-cia-9-1327">Correspondence: Stephen E Borst, Geriatric Research, Education and Clinical Center, Malcom Randall VA Medical Center, 1601 SW Archer Rd, Gainesville, FL 32608-1197, USA, Tel +1 352 374 6114, Fax +1 352 271 4550, Email <email>stephen.borst@va.gov</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2014</year></pub-date><volume>9</volume><fpage>1327</fpage><lpage>1333</lpage><permissions><copyright-statement>&#x000a9; 2014 Borst et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Serum concentrations of neuroactive androgens decline in older men and, in some studies, low testosterone is associated with decreased cognitive function and incidence of depression. Existing studies evaluating the effect of testosterone administration on cognition in older men have been largely inconclusive, with some studies reporting minor to moderate cognitive benefit, while others indicate no cognitive effect. Our objective was to assess the cognitive effects of treating older hypogonadal men for 1 year with a supraphysiological dose of testosterone, either alone or in combination with finasteride (a type II 5&#x003b1;-reductase inhibitor), in order to determine whether testosterone produces cognitive benefit and whether suppressed dihydrotestosterone influences cognition. Sixty men aged &#x02265;60 years with a serum testosterone concentration of &#x02264;300 ng/dL or bioavailable testosterone &#x02264;70 ng/dL and no evidence of cognitive impairment received testosterone-enanthate (125 mg/week) versus vehicle, paired with finasteride (5 mg/day) versus placebo using a 2&#x000d7;2 factorial design. Testosterone caused a small decrease in depressive symptoms as assessed by the Geriatric Depression Scale and a moderate increase in visuospatial memory as assessed by performance on a recall trial of the Rey-Osterrieth Complex Figure Test. Finasteride caused a small increase in performance on the Benton Judgment of Line Orientation test. In total, major improvements in cognition were not observed either with testosterone or finasteride. Further studies are warranted to determine if testosterone replacement may improve cognition in other domains.</p></abstract><kwd-group><title>Keywords</title><kwd>cognition</kwd><kwd>depression</kwd><kwd>5 alpha reductase</kwd><kwd>testosterone enanthate</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Loss of testosterone in older men is associated with a substantial long-term impairment in visual and verbal memory, visuospatial functioning, visuomotor scanning, and visual memory,<xref rid="b1-cia-9-1327" ref-type="bibr">1</xref> and with increased incidence and earlier onset of depression.<xref rid="b2-cia-9-1327" ref-type="bibr">2</xref> These findings are supported by rodent studies in which orchiectomy has been shown to impair spatial memory in Y-maze testing<xref rid="b3-cia-9-1327" ref-type="bibr">3</xref> and Morris water maze testing,<xref rid="b4-cia-9-1327" ref-type="bibr">4</xref> with testosterone administration preserving memory. Despite this evidence, a recent clinical study indicates that short-term (6 weeks) androgen deprivation does not significantly impair cognition (assessed in a variety of domains) in men.<xref rid="b5-cia-9-1327" ref-type="bibr">5</xref></p><p>Existing studies of testosterone administration in older men are typically 1 year or less in duration and have demonstrated only moderate improvements in visuospatial cognition, but not in other domains such as verbal cognition or mood. For example, Janowsky et al treated older eugonadal men for 3 months with testosterone by transdermal patch (15 mg/day). Testosterone improved performance on the block design subtest of the Wechsler Adult Intelligence Scale (WAIS) &#x02013; Revised, but did not improve performance on other cognitive tests. The latter included vocabulary subtest of the WAIS, California Verbal Learning Test, Profile of Mood States, Trail Making Tests A and B, and Grooved Pegboard Test.<xref rid="b6-cia-9-1327" ref-type="bibr">6</xref> Gray et al<xref rid="b7-cia-9-1327" ref-type="bibr">7</xref> administered graded doses of testosterone (25 to 600 mg/week) to older men and observed that testosterone did not alter mood (measured by the Hamilton Depression Inventory and Young Mania Rating Scale) and produced a marginal improvement in visuospatial cognition (computer-based checkerboard test). Cherrier et al<xref rid="b8-cia-9-1327" ref-type="bibr">8</xref> treated older men with testosterone (100 mg/week, intramuscularly [IM]) for 6 weeks and observed improved spatial memory (route test) and constructional abilities (WAIS block design subtest) and increased route test and word list recall.<xref rid="b9-cia-9-1327" ref-type="bibr">9</xref> In contrast, Vaughan et al<xref rid="b10-cia-9-1327" ref-type="bibr">10</xref> administered testosterone (200 mg biweekly, IM) and failed to demonstrate improvement in visuospatial function or visual memory using the Benton Judgment of Line Orientation test and Benton Visual Retention test, respectively. As such, some inconsistency exists in the literature regarding the effects of testosterone administration on cognitive function in older men.</p><p>Our objective was to determine whether treatment of older hypogonadal men with a supraphysiological dose of testosterone for 1 year reduces depressive symptoms, improves wellbeing, and improves visuospatial cognition, and whether co-treatment with finasteride influences these results. We have recently shown that treatment with testosterone plus finasteride provides musculoskeletal and lipolytic benefits without prostate enlargement,<xref rid="b11-cia-9-1327" ref-type="bibr">11</xref> providing sound rationale for this combination pharmacologic therapy. A second objective was to determine whether finasteride has any effects on cognition.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="methods"><title>Study design and subject selection</title><p>Qualifying participants were men aged 60 years or more who had a total serum testosterone level of &#x02264;300 ng/dL or a bioavailable testosterone (BioT) level of &#x02264;70 ng/dL. Participants were randomized to one of four treatment groups &#x02013; vehicle&#x02013; placebo, testosterone-enanthate (TE)&#x02013;placebo, vehicle&#x02013; finasteride, or TE&#x02013;finasteride &#x02013; using a 2&#x000d7;2 factorial design. A total of 60 subjects were randomized, 16 to vehicle plus placebo, 13 to vehicle plus finasteride, 14 to TE plus placebo, and 17 to TE plus finasteride. Treatment lasted 12 months and consisted of Proscar<sup>&#x000ae;</sup> (Merck &#x00026; Co., Inc., Whitehouse Station, NJ, USA) (5 mg/day finasteride, per oral) versus placebo, and Delatestryl<sup>&#x000ae;</sup> (Novartis International AG, Basel, Switzerland) (125 mg/week TE, IM) versus vehicle. Proscar<sup>&#x000ae;</sup> and matching placebo were donated by Merck &#x00026; Co., Inc. Delatestryl<sup>&#x000ae;</sup> was donated by Novartis International AG and matching vehicle was prepared by WestLab Pharmacy, Gainesville, FL, USA. Participants were not paid for participation other than receiving reimbursement for travel mileage.</p><p>This study was approved by the Institutional Review Board of the University of Florida. All participants gave written informed consent. Potential participants underwent screening to determine eligibility, including structured medical history, blood acquisition (performed twice between 8 am and 10 am, separated by at least 30 minutes), and a physical exam, as previously reported.<xref rid="b11-cia-9-1327" ref-type="bibr">11</xref> Two blood samples were obtained during screening because the Endocrine Society recommends repeated measurements to confirm low testosterone prior to initiating testosterone treatment.<xref rid="b12-cia-9-1327" ref-type="bibr">12</xref></p><p>We excluded individuals who failed the Mini-Cog test<xref rid="b13-cia-9-1327" ref-type="bibr">13</xref> to ensure that participants did not present with dementia and that they could fully understood the study protocol. We also excluded: those with a history of prostate or breast cancer, severe benign prostatic hypertrophy, American Urological Society/International Prostate Symptom Score (AUA/IPSS) score &#x02265;25, class 3 or 4 congestive heart failure, sleep apnea, hematocrit &#x0003e;49%, prostate specific antigen &#x02265;2.6 ng/mL, body mass index &#x0003e;35, or orthopedic limitations (precluding strength testing); or those who had received testosterone within 4 weeks, finasteride/dutasteride within 6 months, or who were taking Coumadin<sup>&#x000ae;</sup> (a contraindication for IM injections).</p></sec><sec><title>Protection from risks</title><p>Participants underwent thorough health screenings every 3 months throughout the study, as previously reported.<xref rid="b11-cia-9-1327" ref-type="bibr">11</xref> Participants were removed from the study if the following occurred: hematocrit &#x02265;54%; serum prostate specific antigen &#x02265;4.0; increase in AUA/IPSS &#x02265;4 points; or if gynecomastia or peripheral edema were noted at physical exam.</p></sec><sec><title>Hormone assays</title><p>Serum samples were obtained 1 week after TE/vehicle injection. Total testosterone was assessed in the Clinical Laboratory, Malcom Randall VA Medical Center by Cobas<sup>&#x000ae;</sup> (Hoffman-La Roche Ltd., Basel, Switzerland) electrochemiluminescence immunoassay (intra-assay coefficient of variance [CV] =2.9%, inter-assay CV =3.4%). Serum samples were stored at &#x02212;80&#x000b0;C and analyzed for estradiol (E2) by ELISA (enzyme-linked immunosorbent assay; American Laboratory Products, Salem, NH, USA) (intra-assay CV =7.6%, inter-assay CV =8.8%). BioT and bioavailable estradiol (BioE2) were assessed by ammonium sulfate precipitation of samples spiked with <sup>3</sup>H-testosterone or <sup>3</sup>H-E2.<xref rid="b14-cia-9-1327" ref-type="bibr">14</xref> Dihydrotestosterone (DHT) was assessed by liquid chromatography &#x02013; mass spectroscopy &#x02013; mass spectroscopy at Laboratory Corp of America (Calabasas Hills, CA, USA) (intra-assay CV =8.6%, inter-assay CV =9.9%).</p></sec><sec><title>Cognitive testing</title><p>Cognitive testing was performed at baseline and after 3, 6, 9, and 12 months of treatment. Life Satisfaction Index A and B were used to measure multiple components of psychological wellbeing, with a higher score indicating greater wellbeing.<xref rid="b15-cia-9-1327" ref-type="bibr">15</xref> The Geriatric Depression Scale (GDS) short form was used to assess depressive symptoms, with a higher score indicating more depressive symptoms.<xref rid="b16-cia-9-1327" ref-type="bibr">16</xref>,<xref rid="b17-cia-9-1327" ref-type="bibr">17</xref> The GDS short form consists of the 15 items from the GDS long form that have the highest correlation with depressive symptoms.</p><p>Trail Making Test A (subject draws a line connecting a sequence of numbers in ascending order with a pencil) was used to assess attention. Trail Making Test B (subject draws a line connecting an alternating sequence of numbers and letters in ascending order with a pencil) was used to assess executive functioning.<xref rid="b18-cia-9-1327" ref-type="bibr">18</xref> Trail Making Tests are scored as time (seconds) taken to successfully complete the task. Benton Judgment of Line Orientation test Form H was used to assess visuospatial skills, with a higher score indicating better performance.<xref rid="b19-cia-9-1327" ref-type="bibr">19</xref> This is a 30-item task in which the subject must match a pair of angled lines appearing on the stimulus drawing to two identically oriented lines (out of eleven choices) drawn below the stimulus. The Rey-Osterrieth Complex Figure Test was used to assess visuospatial constructional functions, visuographic memory, and some aspects of planning.<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref> The subject was asked to make a copy of a stimulus drawing comprised of a complex design, which was then scored on 18 identifiable details with a maximum score of 36 points possible and a higher score indicating better performance. The subject then drew the figure from memory 5 minutes later, and again 30 minutes later. Drawings were scored by a licensed neuropsychologist (CF).</p></sec><sec><title>Musculoskeletal assessment</title><p>Muscle strength was assessed as one-repetition maximal strength on a selectorized resistance exercise machine for six upper- and lower-body exercises. Body composition was assessed by dual x-ray absorptiometry using a General Electric Lunar Prodigy fan-beam densitometer (Fairfield, CT, USA). Prostate volume was assessed by transrectal ultrasound sizing using a General Electric LOGICQ P5 scanning system (General Electric, Fairfield, CT, USA).</p></sec><sec sec-type="methods"><title>Statistical model and analysis</title><p>The following mixed effects models were used to fit the data with three covariance structures considered &#x02013; compound symmetry, autoregressive (<xref ref-type="disp-formula" rid="fd1-cia-9-1327">Equation 1</xref>), and unstructured &#x02013; as shown in the following:
<disp-formula id="fd1-cia-9-1327"><mml:math id="mm1"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mrow><mml:mtext>ijk</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:mtext>trt</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>=</mml:mo><mml:mtext>1</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mtext>I</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>k</mml:mtext><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="2.7em"/><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>9</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="2.7em"/><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>9</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mtext>ijk</mml:mtext></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math><label>(1)</label></disp-formula>
<disp-formula id="fd2-cia-9-1327"><mml:math id="mm2"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mrow><mml:mtext>ijk</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mrow><mml:mtext>trt</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mspace width="2.7em"/><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mspace width="0.2em"/><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>9</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mtext>ijk</mml:mtext></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math><label>(2)</label></disp-formula></p><p>where y<sub>ijk</sub> is the response (ie, change-depression, etc) of subject j, measured at time point k with respect to the change from the baseline, under treatment I; I(x= value) is the indicator function (ie, 1 if x= value and 0 otherwise); &#x003b1;<sub>trt</sub> represents the treatment effect; &#x003b1;<sub>1</sub>&#x02013;&#x003b1;<sub>3</sub> represent the time effect; &#x003b1;<sub>4</sub>&#x02013;&#x003b1;<sub>6</sub> represent the interactions between time and treatment effects; u<sub>ij</sub> is the cluster effect due to subject j under treatment i and is assumed to follow N(0,&#x02211;) with &#x02211; being the covariance matrix of 4&#x000d7;4 dimension; and u<sub>ij</sub> characterizes the correlation for the responses from subject j. Three model selection criteria were used to select the best-fit model among the six candidate models for the data, namely Akaike information criterion, corrected Akaike information criterion, and Bayesian information criterion. &#x003b5;<sub>ijk</sub> is the random measurement error following normal distribution. <italic>P</italic>-values &#x02264;0.05 were considered statistically significant. Analyses of results reported are based on the selected best-fit model.</p></sec><sec><title>Nontechnical description of statistics</title><p>We chose the linear mixed model above for two reasons: first, it has the advantage over the alternative of pre-/post-differences in that it utilizes all the time point data; and second, it is more robust against missing data. As a secondary analysis, for the variable that we found to be significant on the main testosterone effect, we applied the same analysis separately to the two subgroups (one with and one without finasteride) to see if testosterone differences were dependent on finasteride. The study was powered on the primary outcomes of Borst et al<xref rid="b11-cia-9-1327" ref-type="bibr">11</xref> and not for cognitive end points.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The musculoskeletal findings and hormone concentrations from this study have been published.<xref rid="b11-cia-9-1327" ref-type="bibr">11</xref> Briefly, testosterone administration increased maximal muscle strength by 8%&#x02013;14% (on all six exercises), increased bone mineral density by 1.96% in the hip and by 4.19% in the lumbar spine, reduced fat mass by 3.87 kg, and increasing prostate volume by 11.4 cm<sup>3</sup>. Coadministration of finasteride prevented testosterone-induced prostate enlargement, but did not affect other responses to testosterone. TE elevated nadir testosterone and BioT, representing 1.8-fold and 2.2-fold increases over baseline, respectively. Coadministration of finasteride did not affect those increases. TE elevated E2 and BioE2, representing 1.7-fold and 2.2-fold increases over baseline, respectively. Coadministration of finasteride did not affect those increases. TE elevated serum DHT by 2.4-fold and finasteride lowered DHT by 65%.</p><p>Subject baseline characteristics are shown in <xref ref-type="table" rid="t1-cia-9-1327">Table 1</xref>. Treatment effects of testosterone and finasteride are shown in <xref ref-type="table" rid="t2-cia-9-1327">Table 2</xref>. TE administration resulted in statistically significant reduction in depressive symptoms on the GDS by 0.74 points on a 15 point scale, with most of the change occurring within the first 3 months of treatment. TE also significantly improved performance on the 30-minute recall trial of the Rey-Osterrieth Complex Figure Test (Rey30) by 2.87 points on a 36 point scale. In order to test the hypothesis that the true population effect size on GDS or Rey30 for testosterone versus placebo is the same whether finasteride is given or not, we applied the same analyses to the two subgroups (ie, with finasteride versus without). <italic>P</italic>-values of 0.48 and 0.72 were obtained for GDS and Rey30, respectively, indicating that no testosterone and finasteride interaction exists for either end point. Finasteride significantly improved performance in the Benton Judgment of Line Orientation test by 1.89 points on a 30 point scale.</p><p>Correlations between serum hormones and cognitive performance at baseline are shown in <xref ref-type="table" rid="t3-cia-9-1327">Table 3</xref>. Higher baseline E2 (<italic>P</italic>=0.039) and BioE2 (<italic>P</italic>=0.050) were positively associated with wellbeing on the Life Satisfaction Index A test, but not on the Life Satisfaction Index B. Increased age was associated with fewer depressive symptoms on the GDS (<italic>P</italic>=0.014), and with increased wellbeing as assessed by Life Satisfaction Index A (<italic>P</italic>=0.006) and B (<italic>P</italic>=0.047), but with poorer performance on the Trail Making Test A (<italic>P</italic>&#x0003c;0.001) and Trail Making Test B (<italic>P</italic>=0.006) tests. The positive effect of TE on depressive symptoms was unchanged when the data were reanalyzed and controlled for age as a covariate.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The main findings of this study are that testosterone treatment reduced depressive symptoms and improved visuospatial memory on the Rey30. The presence of finasteride did not inhibit these effects. In addition, finasteride administration produced an unexpected minor increase in visuospatial skill on the Benton Judgment of Line Orientation test. Higher serum E2 and BioE2 values at baseline were correlated with a greater sense of wellbeing on Life Satisfaction Index A and B. Increased age was associated with improved scores on the GDS and Life Satisfaction Index A and B.</p><p>A review by Holland et al shows that existing studies on the effects of testosterone administration on depression in older men have produced mixed results.<xref rid="b21-cia-9-1327" ref-type="bibr">21</xref> Haren et al treated older men for 1 year with an oral dose of testosterone undecanoate that produced only a small increase in serum testosterone and found that treatment did not affect scores on the GDS.<xref rid="b22-cia-9-1327" ref-type="bibr">22</xref> Vaughan et al treated older men with a supraphysiologic dose of testosterone for 36 months and found that scores on the Beck Depression Scale were unchanged.<xref rid="b10-cia-9-1327" ref-type="bibr">10</xref> However, other studies have reported positive effects of testosterone on mood. Pope et al treated older hypogonadal men with refractory depression for 8 weeks with a moderate dose of testosterone and found improvement on the Hamilton Depression Rating Scale.<xref rid="b23-cia-9-1327" ref-type="bibr">23</xref> Wang et al treated older hypogonadal men with testosterone gel for 3 months and found that testosterone increased self-assessed positive moods and decreased negative moods.<xref rid="b24-cia-9-1327" ref-type="bibr">24</xref> Perry et al treated older men with major depression for 6 weeks with a supraphysiological dose of testosterone and found an improvement in Hamilton Depression Rating Scale scores only in men with onset of depression at age &#x02265;45 years.<xref rid="b25-cia-9-1327" ref-type="bibr">25</xref> Shores et al reported that testosterone gel improved Hamilton Depression Rating Scale scores in hypogonadal men with minor depression.<xref rid="b26-cia-9-1327" ref-type="bibr">26</xref> We observed that 12 months of testosterone administration produced an improvement in scores on the GDS.</p><p>Existing studies on the effects of testosterone on visuospatial cognition have also produced mixed results. Janowsky et al treated older men for 12 weeks with a transdermal dose of testosterone sufficient to raise serum testosterone by 50% and found a significant improvement on the block design subtest of the WAIS.<xref rid="b6-cia-9-1327" ref-type="bibr">6</xref> Cherrier et al treated older men with mild cognitive impairment with supraphysiological testosterone for 6 weeks and also found improved performance on the block design subtest of the WAIS.<xref rid="b8-cia-9-1327" ref-type="bibr">8</xref> However, Vaughan et al,<xref rid="b10-cia-9-1327" ref-type="bibr">10</xref> Haren et al,<xref rid="b22-cia-9-1327" ref-type="bibr">22</xref> Gray et al,<xref rid="b7-cia-9-1327" ref-type="bibr">7</xref> and Young et al<xref rid="b5-cia-9-1327" ref-type="bibr">5</xref> have all treated older men with testosterone and found no changes in visuospatial cognition. However, we found that testosterone improved visuospatial cognition as assessed by the Rey-Osterrieth Complex Figure Test. We also found that finasteride improved visuospatial performance on the Benton Judgment of Line Orientation test. Finasteride blocks tissue-specific conversion of testosterone to DHT, resulting in somewhat higher serum concentrations of testosterone and E2. However, the mechanism by which finasteride might improve visuospatial cognition is unclear.</p><p>We found that increased age was associated with poorer performance on the Trail Making Tests A and B, with fewer depressive symptoms on the GDS, and with increased wellbeing as assessed by Life Satisfaction Index A and B. Normative studies show that performance on Trail Making Tests declines with age.<xref rid="b27-cia-9-1327" ref-type="bibr">27</xref> However, in similar studies, age is not associated with lower depression scores<xref rid="b28-cia-9-1327" ref-type="bibr">28</xref> or improved Life Satisfaction Index scores.<xref rid="b29-cia-9-1327" ref-type="bibr">29</xref> The association of increased age with improved depression and Life Satisfaction Index scores may result from the fact that the oldest subjects in our study would have had to be exceptionally healthy in order to participate in a study demanding intensive subject participation.</p><p>Beneficial cognitive effects of testosterone may result directly from binding of testosterone to androgen receptors or indirectly following conversion of testosterone to DHT 5-alpha reductase. There is evidence that DHT specifically reduces neuroinflammation.<xref rid="b30-cia-9-1327" ref-type="bibr">30</xref> In humans, it has been shown that the cerebral cortex<xref rid="b31-cia-9-1327" ref-type="bibr">31</xref> and hippocampus<xref rid="b32-cia-9-1327" ref-type="bibr">32</xref> express 5-alpha reductase isoform I, but not isoform II. Therefore, it is unlikely that finasteride significantly lowers DHT concentrations in these regions. Our data are consistent with the hypothesis that, whether or not cognitive benefits of testosterone require conversion of testosterone to DHT, finasteride would not be expected to reduce those benefits.</p><p>Consistent strong cognitive benefits resulting from testosterone administration have not been identified to date. However, a limited number of cognitive domains have been the subject of past studies, leaving the question of whether benefits may occur in domains that have not yet been tested. A large amount of literature supports the role of testosterone in social dominance and approach motivation.<xref rid="b33-cia-9-1327" ref-type="bibr">33</xref>,<xref rid="b34-cia-9-1327" ref-type="bibr">34</xref> Anecdotally, some subjects report that testosterone treatment increases feelings of energy and motivation. However, the effects of testosterone treatment on motivation in hypogonadal men has not been tested. Aarts and van Honk have reported that acute administration of testosterone to young women increased motivation, as assessed by a computerized test of responses to neutral nonsexual cues.<xref rid="b35-cia-9-1327" ref-type="bibr">35</xref> Future studies are warranted to investigate the potential benefits of testosterone on the areas of drive, motivation, and other as yet untested cognitive domains.</p><p>In conclusion, we report that testosterone produced small improvements in depressive symptoms and visuospatial cognition. Our results are generally consistent with the literature, which shows that testosterone treatment produces somewhat inconsistent improvements in cognition.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cia-9-1327"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffat</surname><given-names>SD</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Metter</surname><given-names>EJ</given-names></name><name><surname>Blackman</surname><given-names>MR</given-names></name><name><surname>Harman</surname><given-names>SM</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name></person-group><article-title>Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><issue>11</issue><fpage>5001</fpage><lpage>5007</lpage><pub-id pub-id-type="pmid">12414864</pub-id></element-citation></ref><ref id="b2-cia-9-1327"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shores</surname><given-names>MM</given-names></name><name><surname>Moceri</surname><given-names>VM</given-names></name><name><surname>Sloan</surname><given-names>KL</given-names></name><name><surname>Matsumoto</surname><given-names>AM</given-names></name><name><surname>Kivlahan</surname><given-names>DR</given-names></name></person-group><article-title>Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity</article-title><source>J Clin Psychiatry</source><year>2005</year><volume>66</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15669883</pub-id></element-citation></ref><ref id="b3-cia-9-1327"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawley</surname><given-names>WR</given-names></name><name><surname>Grissom</surname><given-names>EM</given-names></name><name><surname>Martin</surname><given-names>RC</given-names></name><name><surname>Halmos</surname><given-names>MB</given-names></name><name><surname>Bart</surname><given-names>CL</given-names></name><name><surname>Dohanich</surname><given-names>GP</given-names></name></person-group><article-title>Testosterone modulates spatial recognition memory in male rats</article-title><source>Horm Behav</source><year>2013</year><volume>63</volume><issue>4</issue><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">23481590</pub-id></element-citation></ref><ref id="b4-cia-9-1327"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>H</given-names></name><name><surname>Akishita</surname><given-names>M</given-names></name><name><surname>Akiyoshi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT1</article-title><source>PloS One</source><year>2012</year><volume>7</volume><issue>1</issue><fpage>e29598</fpage><pub-id pub-id-type="pmid">22238626</pub-id></element-citation></ref><ref id="b5-cia-9-1327"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>LA</given-names></name><name><surname>Neiss</surname><given-names>MB</given-names></name><name><surname>Samuels</surname><given-names>MH</given-names></name><name><surname>Roselli</surname><given-names>CE</given-names></name><name><surname>Janowsky</surname><given-names>JS</given-names></name></person-group><article-title>Cognition is not modified by large but temporary changes in sex hormones in men</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><issue>1</issue><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">19880786</pub-id></element-citation></ref><ref id="b6-cia-9-1327"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janowsky</surname><given-names>JS</given-names></name><name><surname>Oviatt</surname><given-names>SK</given-names></name><name><surname>Orwoll</surname><given-names>ES</given-names></name></person-group><article-title>Testosterone influences spatial cognition in older men</article-title><source>Behav Neurosci</source><year>1994</year><volume>108</volume><issue>2</issue><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">8037876</pub-id></element-citation></ref><ref id="b7-cia-9-1327"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>PB</given-names></name><name><surname>Singh</surname><given-names>AB</given-names></name><name><surname>Woodhouse</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><issue>7</issue><fpage>3838</fpage><lpage>3846</lpage><pub-id pub-id-type="pmid">15827094</pub-id></element-citation></ref><ref id="b8-cia-9-1327"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherrier</surname><given-names>MM</given-names></name><name><surname>Matsumoto</surname><given-names>AM</given-names></name><name><surname>Amory</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>12</issue><fpage>2063</fpage><lpage>2068</lpage><pub-id pub-id-type="pmid">15985573</pub-id></element-citation></ref><ref id="b9-cia-9-1327"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherrier</surname><given-names>MM</given-names></name><name><surname>Matsumoto</surname><given-names>AM</given-names></name><name><surname>Amory</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men</article-title><source>Psychoneuroendocrinology</source><year>2007</year><volume>32</volume><issue>1</issue><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">17145137</pub-id></element-citation></ref><ref id="b10-cia-9-1327"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>FC</given-names></name><name><surname>Tenover</surname><given-names>JL</given-names></name></person-group><article-title>Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone</article-title><source>J Androl</source><year>2007</year><volume>28</volume><issue>6</issue><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">17609296</pub-id></element-citation></ref><ref id="b11-cia-9-1327"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borst</surname><given-names>SE</given-names></name><name><surname>Yarrow</surname><given-names>JF</given-names></name><name><surname>Conover</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial</article-title><source>Am J Physiol Endocrinol Metab</source><year>2014</year><volume>306</volume><issue>4</issue><fpage>E433</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">24326421</pub-id></element-citation></ref><ref id="b12-cia-9-1327"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhasin</surname><given-names>S</given-names></name><name><surname>Cunningham</surname><given-names>GR</given-names></name><name><surname>Hayes</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><issue>6</issue><fpage>2536</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">20525905</pub-id></element-citation></ref><ref id="b13-cia-9-1327"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Severo</surname><given-names>M</given-names></name><name><surname>Fraga</surname><given-names>S</given-names></name><name><surname>Barros</surname><given-names>H</given-names></name></person-group><article-title>Mini-Cog and Mini-Mental State Examination: agreement in a cross-sectional study with an elderly sample</article-title><source>Dement Geriatr Cogn Disord</source><year>2012</year><volume>33</volume><issue>2&#x02013;3</issue><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">22508578</pub-id></element-citation></ref><ref id="b14-cia-9-1327"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>A</given-names></name><name><surname>Verdonck</surname><given-names>L</given-names></name><name><surname>Kaufman</surname><given-names>JM</given-names></name></person-group><article-title>A critical evaluation of simple methods for the estimation of free testosterone in serum</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><fpage>3666</fpage><lpage>3672</lpage><pub-id pub-id-type="pmid">10523012</pub-id></element-citation></ref><ref id="b15-cia-9-1327"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suba&#x0015f;i</surname><given-names>F</given-names></name><name><surname>Hayran</surname><given-names>O</given-names></name></person-group><article-title>Evaluation of life satisfaction index of the elderly people living in nursing homes</article-title><source>Arch Gerontol Geriatr</source><year>2005</year><volume>41</volume><issue>1</issue><fpage>23</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15911035</pub-id></element-citation></ref><ref id="b16-cia-9-1327"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granger</surname><given-names>CV</given-names></name><name><surname>Cotter</surname><given-names>AC</given-names></name><name><surname>Hamilton</surname><given-names>BB</given-names></name><name><surname>Fiedler</surname><given-names>RC</given-names></name><name><surname>Hens</surname><given-names>MM</given-names></name></person-group><article-title>Functional assessment scales: a study of persons with multiple sclerosis</article-title><source>Arch Phys Med Rehabil</source><year>1990</year><volume>71</volume><issue>11</issue><fpage>870</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">2222154</pub-id></element-citation></ref><ref id="b17-cia-9-1327"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stineman</surname><given-names>MG</given-names></name><name><surname>Shea</surname><given-names>JA</given-names></name><name><surname>Jette</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories</article-title><source>Arch Phys Med Rehabil</source><year>1996</year><volume>77</volume><issue>11</issue><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">8931518</pub-id></element-citation></ref><ref id="b18-cia-9-1327"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hankee</surname><given-names>LD</given-names></name><name><surname>Preis</surname><given-names>SR</given-names></name><name><surname>Beiser</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Qualitative neuropsychological measures: normative data on executive functioning tests from the Framingham offspring study</article-title><source>Exp Aging Res</source><year>2013</year><volume>39</volume><issue>5</issue><fpage>515</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">24151914</pub-id></element-citation></ref><ref id="b19-cia-9-1327"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodard</surname><given-names>JL</given-names></name><name><surname>Benedict</surname><given-names>RH</given-names></name><name><surname>Salthouse</surname><given-names>TA</given-names></name><name><surname>Toth</surname><given-names>JP</given-names></name><name><surname>Zgaljardic</surname><given-names>DJ</given-names></name><name><surname>Hancock</surname><given-names>HE</given-names></name></person-group><article-title>Normative data for equivalent, parallel forms of the Judgment of Line Orientation Test</article-title><source>J Clin Exp Neuropsychol</source><year>1998</year><volume>20</volume><issue>4</issue><fpage>457</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9892049</pub-id></element-citation></ref><ref id="b20-cia-9-1327"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reedy</surname><given-names>SD</given-names></name><name><surname>Boone</surname><given-names>KB</given-names></name><name><surname>Cottingham</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Cross validation of the Lu and colleagues (2003) Rey-Osterrieth Complex Figure Test effort equation in a large known-group sample</article-title><source>Arch Clin Neuropsychol</source><year>2013</year><volume>28</volume><issue>1</issue><fpage>30</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23232864</pub-id></element-citation></ref><ref id="b21-cia-9-1327"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>J</given-names></name><name><surname>Bandelow</surname><given-names>S</given-names></name><name><surname>Hogervorst</surname><given-names>E</given-names></name></person-group><article-title>Testosterone levels and cognition in elderly men: a review</article-title><source>Maturitas</source><year>2011</year><volume>69</volume><issue>4</issue><fpage>322</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">21696899</pub-id></element-citation></ref><ref id="b22-cia-9-1327"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haren</surname><given-names>MT</given-names></name><name><surname>Wittert</surname><given-names>GA</given-names></name><name><surname>Chapman</surname><given-names>IM</given-names></name><name><surname>Coates</surname><given-names>P</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name></person-group><article-title>Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status</article-title><source>Maturitas</source><year>2005</year><volume>50</volume><issue>2</issue><fpage>124</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">15653010</pub-id></element-citation></ref><ref id="b23-cia-9-1327"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>HG</given-names><suffix>Jr</suffix></name><name><surname>Cohane</surname><given-names>GH</given-names></name><name><surname>Kanayama</surname><given-names>G</given-names></name><name><surname>Siegel</surname><given-names>AJ</given-names></name><name><surname>Hudson</surname><given-names>JI</given-names></name></person-group><article-title>Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial</article-title><source>Am J Psychiatry</source><year>2003</year><volume>160</volume><issue>1</issue><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">12505808</pub-id></element-citation></ref><ref id="b24-cia-9-1327"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Swerdloff</surname><given-names>RS</given-names></name><name><surname>Iranmanesh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><issue>8</issue><fpage>2839</fpage><lpage>2853</lpage><pub-id pub-id-type="pmid">10946892</pub-id></element-citation></ref><ref id="b25-cia-9-1327"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>PJ</given-names></name><name><surname>Yates</surname><given-names>WR</given-names></name><name><surname>Williams</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Testosterone therapy in late-life major depression in males</article-title><source>J Clin Psychiatry</source><year>2002</year><volume>63</volume><issue>12</issue><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">12523867</pub-id></element-citation></ref><ref id="b26-cia-9-1327"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shores</surname><given-names>MM</given-names></name><name><surname>Kivlahan</surname><given-names>DR</given-names></name><name><surname>Sadak</surname><given-names>TI</given-names></name><name><surname>Li</surname><given-names>EJ</given-names></name><name><surname>Matsumoto</surname><given-names>AM</given-names></name></person-group><article-title>A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression)</article-title><source>J Clin Psychiatry</source><year>2009</year><volume>70</volume><issue>7</issue><fpage>1009</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">19653976</pub-id></element-citation></ref><ref id="b27-cia-9-1327"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tombaugh</surname><given-names>TN</given-names></name></person-group><article-title>Trail Making Test A and B: normative data stratified by age and education</article-title><source>Arch Clin Neuropsychol</source><year>2004</year><volume>19</volume><issue>2</issue><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">15010086</pub-id></element-citation></ref><ref id="b28-cia-9-1327"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>RG</given-names></name><name><surname>Chisholm</surname><given-names>BJ</given-names></name><name><surname>Marsh</surname><given-names>NV</given-names></name><name><surname>Godfrey</surname><given-names>HP</given-names></name></person-group><article-title>Some normative, reliability, and factor analytic data for the revised UCLA Loneliness Scale</article-title><source>J Clin Psychol</source><year>1988</year><volume>44</volume><issue>2</issue><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">3360935</pub-id></element-citation></ref><ref id="b29-cia-9-1327"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavot</surname><given-names>W</given-names></name><name><surname>Diener</surname><given-names>E</given-names></name><name><surname>Colvin</surname><given-names>CR</given-names></name><name><surname>Sandvik</surname><given-names>E</given-names></name></person-group><article-title>Further validation of the Satisfaction with Life Scale: evidence for the cross-method convergence of well-being measures</article-title><source>J Pers Assess</source><year>1991</year><volume>57</volume><issue>1</issue><fpage>149</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">1920028</pub-id></element-citation></ref><ref id="b30-cia-9-1327"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giatti</surname><given-names>S</given-names></name><name><surname>Boraso</surname><given-names>M</given-names></name><name><surname>Melcangi</surname><given-names>RC</given-names></name><name><surname>Viviani</surname><given-names>B</given-names></name></person-group><article-title>Neuroactive steroids, their metabolites, and neuroinflammation</article-title><source>J Mol Endocrinol</source><year>2012</year><volume>49</volume><issue>3</issue><fpage>R125</fpage><lpage>R134</lpage><pub-id pub-id-type="pmid">22966132</pub-id></element-citation></ref><ref id="b31-cia-9-1327"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steckelbroeck</surname><given-names>S</given-names></name><name><surname>Watzka</surname><given-names>M</given-names></name><name><surname>Reichelt</surname><given-names>R</given-names></name><etal/></person-group><article-title>Characterization of the 5alpha-reductase-3alpha-hydroxysteroid dehydrogenase complex in the human brain</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><issue>3</issue><fpage>1324</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">11238528</pub-id></element-citation></ref><ref id="b32-cia-9-1327"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoffel-Wagner</surname><given-names>B</given-names></name><name><surname>Beyenburg</surname><given-names>S</given-names></name><name><surname>Watzka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Expression of 5alpha-reductase and 3alpha-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy</article-title><source>Epilepsia</source><year>2000</year><volume>41</volume><issue>2</issue><fpage>140</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">10691110</pub-id></element-citation></ref><ref id="b33-cia-9-1327"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Haushofer</surname><given-names>J</given-names></name><name><surname>Fehr</surname><given-names>E</given-names></name></person-group><article-title>The role of testosterone in social interaction</article-title><source>Trends Cogn Sci</source><year>2011</year><volume>15</volume><issue>6</issue><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">21616702</pub-id></element-citation></ref><ref id="b34-cia-9-1327"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazur</surname><given-names>A</given-names></name><name><surname>Booth</surname><given-names>A</given-names></name></person-group><article-title>Testosterone and dominance in men</article-title><source>Behav Brain Sci</source><year>1998</year><volume>21</volume><issue>3</issue><fpage>353</fpage><lpage>363</lpage><comment>discussion 363&#x02013;397</comment><pub-id pub-id-type="pmid">10097017</pub-id></element-citation></ref><ref id="b35-cia-9-1327"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarts</surname><given-names>H</given-names></name><name><surname>van Honk</surname><given-names>J</given-names></name></person-group><article-title>Testosterone and unconscious positive priming increase human motivation separately</article-title><source>Neuroreport</source><year>2009</year><volume>20</volume><issue>14</issue><fpage>1300</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">19687767</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-cia-9-1327" position="float"><label>Table 1</label><caption><p>Baseline characteristics for participants receiving vehicle&#x02013;placebo, vehicle&#x02013;finasteride, TE&#x02013;placebo, and TE&#x02013;finasteride</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="left" valign="top" rowspan="1" colspan="1">Vehicle&#x02013;placebo</th><th align="left" valign="top" rowspan="1" colspan="1">Vehicle&#x02013;finasteride</th><th align="left" valign="top" rowspan="1" colspan="1">TE&#x02013;placebo</th><th align="left" valign="top" rowspan="1" colspan="1">TE&#x02013;finasteride</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="left" valign="top" rowspan="1" colspan="1">70.8&#x000b1;9.7</td><td align="left" valign="top" rowspan="1" colspan="1">69.5&#x000b1;9.2</td><td align="left" valign="top" rowspan="1" colspan="1">69.2&#x000b1;8.0</td><td align="left" valign="top" rowspan="1" colspan="1">64.2&#x000b1;4.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="left" valign="top" rowspan="1" colspan="1">30.4&#x000b1;3.4</td><td align="left" valign="top" rowspan="1" colspan="1">28.8&#x000b1;3.9</td><td align="left" valign="top" rowspan="1" colspan="1">29.4&#x000b1;4.6</td><td align="left" valign="top" rowspan="1" colspan="1">31.1&#x000b1;2.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Testosterone, ng/dL</td><td align="left" valign="top" rowspan="1" colspan="1">264&#x000b1;92</td><td align="left" valign="top" rowspan="1" colspan="1">240&#x000b1;110</td><td align="left" valign="top" rowspan="1" colspan="1">245&#x000b1;73</td><td align="left" valign="top" rowspan="1" colspan="1">242&#x000b1;147</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BioT, ng/dL</td><td align="left" valign="top" rowspan="1" colspan="1">46&#x000b1;22</td><td align="left" valign="top" rowspan="1" colspan="1">41&#x000b1;17</td><td align="left" valign="top" rowspan="1" colspan="1">46&#x000b1;17</td><td align="left" valign="top" rowspan="1" colspan="1">44&#x000b1;20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">E2, pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">12.7&#x000b1;9.5</td><td align="left" valign="top" rowspan="1" colspan="1">13.6&#x000b1;7.4</td><td align="left" valign="top" rowspan="1" colspan="1">25.8&#x000b1;34.4</td><td align="left" valign="top" rowspan="1" colspan="1">26.0&#x000b1;30.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BioE2, pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">4.7&#x000b1;3.1</td><td align="left" valign="top" rowspan="1" colspan="1">4.7&#x000b1;2.1</td><td align="left" valign="top" rowspan="1" colspan="1">11.0&#x000b1;17.2</td><td align="left" valign="top" rowspan="1" colspan="1">9.8&#x000b1;9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DHT, ng/dL</td><td align="left" valign="top" rowspan="1" colspan="1">25.2&#x000b1;15.1</td><td align="left" valign="top" rowspan="1" colspan="1">18.9&#x000b1;12.7</td><td align="left" valign="top" rowspan="1" colspan="1">21.4&#x000b1;6.3</td><td align="left" valign="top" rowspan="1" colspan="1">21.9&#x000b1;22.4</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cia-9-1327"><p><bold>Note:</bold> Values are means &#x000b1; standard deviation.</p></fn><fn id="tfn2-cia-9-1327"><p><bold>Abbreviations:</bold> BioE2, bioavailable estradiol; BioT, bioavailable testosterone; BMI, body mass index; DHT, dihydrotestosterone; E2, estradiol; TE, testosterone enanthate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cia-9-1327" position="float"><label>Table 2</label><caption><p>Effects of testosterone and finasteride on cognition</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Cognitive or psychological test</th><th align="left" valign="top" rowspan="1" colspan="1">Time of testing</th><th align="left" valign="top" rowspan="1" colspan="1">Testosterone&#x02013;placebo</th><th align="left" valign="top" rowspan="1" colspan="1">Testosterone&#x02013;finasteride</th><th align="left" valign="top" rowspan="1" colspan="1">Vehicle&#x02013;placebo</th><th align="left" valign="top" rowspan="1" colspan="1">Vehicle&#x02013;finasteride</th><th align="left" valign="top" rowspan="1" colspan="1">Testosterone effect</th><th align="left" valign="top" rowspan="1" colspan="1">Finasteride effect</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Depression<xref rid="b16-cia-9-1327" ref-type="bibr">16</xref>,<xref rid="b17-cia-9-1327" ref-type="bibr">17</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">2.38&#x000b1;1.76</td><td align="left" valign="top" rowspan="1" colspan="1">4.93&#x000b1;2.76</td><td align="left" valign="top" rowspan="1" colspan="1">2.13&#x000b1;1.93</td><td align="left" valign="top" rowspan="1" colspan="1">3.08&#x000b1;3.95</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;0.74 (&#x02212;1.41 to &#x02212;0.06)<break/><italic>P</italic>=0.04<xref ref-type="table-fn" rid="tfn4-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;0.63 (&#x02212;1.31 to 0.06)<break/><italic>P</italic>=0.08</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">&#x02003;15 questions</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">1.80&#x000b1;1.55</td><td align="left" valign="top" rowspan="1" colspan="1">3.23&#x000b1;3.11</td><td align="left" valign="top" rowspan="1" colspan="1">1.67&#x000b1;1.18</td><td align="left" valign="top" rowspan="1" colspan="1">2.90&#x000b1;3.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">1.50&#x000b1;1.51</td><td align="left" valign="top" rowspan="1" colspan="1">5.00&#x000b1;4.80</td><td align="left" valign="top" rowspan="1" colspan="1">1.62&#x000b1;1.80</td><td align="left" valign="top" rowspan="1" colspan="1">2.22&#x000b1;3.90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">0.88&#x000b1;0.64</td><td align="left" valign="top" rowspan="1" colspan="1">3.69&#x000b1;3.86</td><td align="left" valign="top" rowspan="1" colspan="1">2.92&#x000b1;3.26</td><td align="left" valign="top" rowspan="1" colspan="1">1.89&#x000b1;2.98</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">3.33&#x000b1;3.39</td><td align="left" valign="top" rowspan="1" colspan="1">3.73&#x000b1;1.18</td><td align="left" valign="top" rowspan="1" colspan="1">1.83&#x000b1;1.27</td><td align="left" valign="top" rowspan="1" colspan="1">2.88&#x000b1;4.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trail Making Test A<xref rid="b18-cia-9-1327" ref-type="bibr">18</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">37.5&#x000b1;12.9</td><td align="left" valign="top" rowspan="1" colspan="1">36.6&#x000b1;9.23</td><td align="left" valign="top" rowspan="1" colspan="1">44.0&#x000b1;27.0</td><td align="left" valign="top" rowspan="1" colspan="1">46.4&#x000b1;13.0</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;0.64 (&#x02212;5.10 to 3.81)<break/><italic>P</italic>=0.78</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;2.42 (&#x02212;6.83 to 2.00)<break/><italic>P</italic>=0.29</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">&#x02003;Time (seconds)</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">38.5&#x000b1;16.5</td><td align="left" valign="top" rowspan="1" colspan="1">33.5&#x000b1;7.08</td><td align="left" valign="top" rowspan="1" colspan="1">44.3&#x000b1;27.5</td><td align="left" valign="top" rowspan="1" colspan="1">42.1&#x000b1;17.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">32.9&#x000b1;12.3</td><td align="left" valign="top" rowspan="1" colspan="1">31.2&#x000b1;8.14</td><td align="left" valign="top" rowspan="1" colspan="1">36.9&#x000b1;18.7</td><td align="left" valign="top" rowspan="1" colspan="1">39.0&#x000b1;16.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">31.0&#x000b1;12.6</td><td align="left" valign="top" rowspan="1" colspan="1">29.0&#x000b1;6.49</td><td align="left" valign="top" rowspan="1" colspan="1">43.7&#x000b1;44.9</td><td align="left" valign="top" rowspan="1" colspan="1">38.5&#x000b1;13.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">29.1&#x000b1;15.8</td><td align="left" valign="top" rowspan="1" colspan="1">39.5&#x000b1;10.3</td><td align="left" valign="top" rowspan="1" colspan="1">43.7&#x000b1;45.9</td><td align="left" valign="top" rowspan="1" colspan="1">40.0&#x000b1;15.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trail Making Test B<xref rid="b18-cia-9-1327" ref-type="bibr">18</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">111.8&#x000b1;63.7</td><td align="left" valign="top" rowspan="1" colspan="1">106.7&#x000b1;61.8</td><td align="left" valign="top" rowspan="1" colspan="1">122.3&#x000b1;73.9</td><td align="left" valign="top" rowspan="1" colspan="1">122.3&#x000b1;54.5</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;25.15 (&#x02212;52.72 to 2.42)<break/><italic>P</italic>=0.08</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;4.04 (&#x02212;32.36 to 24.29)<break/><italic>P</italic>=0.78</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">&#x02003;Time (seconds)</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">113.3&#x000b1;18.8</td><td align="left" valign="top" rowspan="1" colspan="1">100.8&#x000b1;37.0</td><td align="left" valign="top" rowspan="1" colspan="1">131.8&#x000b1;102.2</td><td align="left" valign="top" rowspan="1" colspan="1">120.3&#x000b1;74.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">110.6&#x000b1;26.3</td><td align="left" valign="top" rowspan="1" colspan="1">97.6&#x000b1;46.7</td><td align="left" valign="top" rowspan="1" colspan="1">137.2&#x000b1;147.8</td><td align="left" valign="top" rowspan="1" colspan="1">106.2&#x000b1;47.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">90.6&#x000b1;43.5</td><td align="left" valign="top" rowspan="1" colspan="1">82.5&#x000b1;27.3</td><td align="left" valign="top" rowspan="1" colspan="1">126.6&#x000b1;152.7</td><td align="left" valign="top" rowspan="1" colspan="1">107.8&#x000b1;16.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">83.8&#x000b1;41.0</td><td align="left" valign="top" rowspan="1" colspan="1">86.5&#x000b1;35.5</td><td align="left" valign="top" rowspan="1" colspan="1">113.3&#x000b1;127.0</td><td align="left" valign="top" rowspan="1" colspan="1">131.0&#x000b1;95.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Life Satisfaction Index A<xref rid="b15-cia-9-1327" ref-type="bibr">15</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">13.8&#x000b1;3.51</td><td align="left" valign="top" rowspan="1" colspan="1">11.3&#x000b1;4.60</td><td align="left" valign="top" rowspan="1" colspan="1">12.6&#x000b1;4.32</td><td align="left" valign="top" rowspan="1" colspan="1">12.0&#x000b1;5.71</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;0.87 (&#x02212;2.18 to 0.44)<break/><italic>P</italic>=0.20</td><td align="left" valign="top" rowspan="5" colspan="1">0.18 (&#x02212;1.15 to 1.51)<break/><italic>P</italic>=0.79</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">&#x02003;Max =20</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">12.6&#x000b1;2.29</td><td align="left" valign="top" rowspan="1" colspan="1">12.2&#x000b1;5.15</td><td align="left" valign="top" rowspan="1" colspan="1">14.1&#x000b1;3.54</td><td align="left" valign="top" rowspan="1" colspan="1">12.1&#x000b1;6.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">13.7&#x000b1;3.33</td><td align="left" valign="top" rowspan="1" colspan="1">11.2&#x000b1;6.16</td><td align="left" valign="top" rowspan="1" colspan="1">13.5&#x000b1;4.56</td><td align="left" valign="top" rowspan="1" colspan="1">14.4&#x000b1;4.95</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">14.7&#x000b1;2.92</td><td align="left" valign="top" rowspan="1" colspan="1">11.5&#x000b1;5.03</td><td align="left" valign="top" rowspan="1" colspan="1">13.1&#x000b1;5.11</td><td align="left" valign="top" rowspan="1" colspan="1">13.4&#x000b1;4.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">15.1&#x000b1;2.71</td><td align="left" valign="top" rowspan="1" colspan="1">12.7&#x000b1;6.25</td><td align="left" valign="top" rowspan="1" colspan="1">13.8&#x000b1;4.76</td><td align="left" valign="top" rowspan="1" colspan="1">12.5&#x000b1;5.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Life Satisfaction Index B<xref rid="b15-cia-9-1327" ref-type="bibr">15</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">19.2&#x000b1;2.49</td><td align="left" valign="top" rowspan="1" colspan="1">15.7&#x000b1;5.03</td><td align="left" valign="top" rowspan="1" colspan="1">18.0&#x000b1;2.90</td><td align="left" valign="top" rowspan="1" colspan="1">17.3&#x000b1;5.79</td><td align="left" valign="top" rowspan="5" colspan="1">0.33 (&#x02212;0.85 to 1.51)<break/><italic>P</italic>=0.58</td><td align="left" valign="top" rowspan="5" colspan="1">0.38 (&#x02212;0.81 to 1.56)<break/><italic>P</italic>=0.54</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">&#x02003;Max =24</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">19.6&#x000b1;0.65</td><td align="left" valign="top" rowspan="1" colspan="1">17.2&#x000b1;4.33</td><td align="left" valign="top" rowspan="1" colspan="1">19.1&#x000b1;3.02</td><td align="left" valign="top" rowspan="1" colspan="1">16.9&#x000b1;4.86</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">19.0&#x000b1;2.91</td><td align="left" valign="top" rowspan="1" colspan="1">16.1&#x000b1;5.97</td><td align="left" valign="top" rowspan="1" colspan="1">18.3&#x000b1;3.61</td><td align="left" valign="top" rowspan="1" colspan="1">16.7&#x000b1;6.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">19.5&#x000b1;1.41</td><td align="left" valign="top" rowspan="1" colspan="1">16.4&#x000b1;4.40</td><td align="left" valign="top" rowspan="1" colspan="1">18.5&#x000b1;4.30</td><td align="left" valign="top" rowspan="1" colspan="1">17.3&#x000b1;5.27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">18.3&#x000b1;2.40</td><td align="left" valign="top" rowspan="1" colspan="1">15.9&#x000b1;4.98</td><td align="left" valign="top" rowspan="1" colspan="1">18.8&#x000b1;3.74</td><td align="left" valign="top" rowspan="1" colspan="1">15.6&#x000b1;6.02</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Benton Judgment of Line Orientation<xref rid="b19-cia-9-1327" ref-type="bibr">19</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">24.5&#x000b1;4.54</td><td align="left" valign="top" rowspan="1" colspan="1">25.8&#x000b1;3.79</td><td align="left" valign="top" rowspan="1" colspan="1">24.6&#x000b1;4.91</td><td align="left" valign="top" rowspan="1" colspan="1">24.3&#x000b1;2.90</td><td align="left" valign="top" rowspan="5" colspan="1">0.59 (&#x02212;0.87 to 2.04)<break/><italic>P</italic>=0.43</td><td align="left" valign="top" rowspan="5" colspan="1">1.89 (0.05 to 3.74)<break/><italic>P</italic>=0.05<xref ref-type="table-fn" rid="tfn4-cia-9-1327">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">25.0&#x000b1;0.73</td><td align="left" valign="top" rowspan="1" colspan="1">25.0&#x000b1;4.22</td><td align="left" valign="top" rowspan="1" colspan="1">25.6&#x000b1;4.55</td><td align="left" valign="top" rowspan="1" colspan="1">25.4&#x000b1;4.35</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x02003;Max =30</td><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">25.9&#x000b1;1.18</td><td align="left" valign="top" rowspan="1" colspan="1">26.0&#x000b1;3.05</td><td align="left" valign="top" rowspan="1" colspan="1">25.0&#x000b1;4.54</td><td align="left" valign="top" rowspan="1" colspan="1">25.1&#x000b1;3.98</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">25.3&#x000b1;4.1</td><td align="left" valign="top" rowspan="1" colspan="1">25.7&#x000b1;3.02</td><td align="left" valign="top" rowspan="1" colspan="1">24.9&#x000b1;6.07</td><td align="left" valign="top" rowspan="1" colspan="1">23.8&#x000b1;3.69</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">25.6&#x000b1;1.97</td><td align="left" valign="top" rowspan="1" colspan="1">26.1&#x000b1;2.66</td><td align="left" valign="top" rowspan="1" colspan="1">24.0&#x000b1;6.52</td><td align="left" valign="top" rowspan="1" colspan="1">25.5&#x000b1;3.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rey0<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">27.9&#x000b1;5.50</td><td align="left" valign="top" rowspan="1" colspan="1">29.2&#x000b1;5.47</td><td align="left" valign="top" rowspan="1" colspan="1">28.8&#x000b1;5.55</td><td align="left" valign="top" rowspan="1" colspan="1">29.3&#x000b1;3.13</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;1.11 (&#x02212;3.53 to 1.30)<break/><italic>P</italic>=0.37</td><td align="left" valign="top" rowspan="5" colspan="1">&#x02212;0.04 (&#x02212;2.46 to 2.39)<break/><italic>P</italic>=0.98</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Copy figure</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">26.8&#x000b1;7.91</td><td align="left" valign="top" rowspan="1" colspan="1">29.3&#x000b1;3.77</td><td align="left" valign="top" rowspan="1" colspan="1">29.0&#x000b1;5.37</td><td align="left" valign="top" rowspan="1" colspan="1">29.6&#x000b1;2.63</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x02003;Max =36</td><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">27.4&#x000b1;2.11</td><td align="left" valign="top" rowspan="1" colspan="1">28.0&#x000b1;4.33</td><td align="left" valign="top" rowspan="1" colspan="1">28.5&#x000b1;5.16</td><td align="left" valign="top" rowspan="1" colspan="1">30.1&#x000b1;2.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">28.0&#x000b1;6.93</td><td align="left" valign="top" rowspan="1" colspan="1">29.0&#x000b1;3.63</td><td align="left" valign="top" rowspan="1" colspan="1">29.2&#x000b1;3.58</td><td align="left" valign="top" rowspan="1" colspan="1">23.8&#x000b1;3.69</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">27.0&#x000b1;8.52</td><td align="left" valign="top" rowspan="1" colspan="1">27.5&#x000b1;4.98</td><td align="left" valign="top" rowspan="1" colspan="1">27.4&#x000b1;4.99</td><td align="left" valign="top" rowspan="1" colspan="1">28.5&#x000b1;3.57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rey5<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">13.3&#x000b1;12.4</td><td align="left" valign="top" rowspan="1" colspan="1">12.06&#x000b1;3.95</td><td align="left" valign="top" rowspan="1" colspan="1">12.3&#x000b1;6.26</td><td align="left" valign="top" rowspan="1" colspan="1">12.5&#x000b1;6.74</td><td align="left" valign="top" rowspan="5" colspan="1">1.38 (&#x02212;1.20 to 3.97)<break/><italic>P</italic>=0.30</td><td align="left" valign="top" rowspan="5" colspan="1">1.98 (&#x02212;0.57 to 4.52)<break/><italic>P</italic>=0.13</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Draw from memory at 5 minutes</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">15.6&#x000b1;7.34</td><td align="left" valign="top" rowspan="1" colspan="1">15.8&#x000b1;5.62</td><td align="left" valign="top" rowspan="1" colspan="1">11.8&#x000b1;8.07</td><td align="left" valign="top" rowspan="1" colspan="1">13.2&#x000b1;3.15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">16.9&#x000b1;8.17</td><td align="left" valign="top" rowspan="1" colspan="1">16.4&#x000b1;4.76</td><td align="left" valign="top" rowspan="1" colspan="1">12.6&#x000b1;7.29</td><td align="left" valign="top" rowspan="1" colspan="1">15.1&#x000b1;5.10</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Max =36</td><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">15.8&#x000b1;8.67</td><td align="left" valign="top" rowspan="1" colspan="1">17.3&#x000b1;3.63</td><td align="left" valign="top" rowspan="1" colspan="1">15.8&#x000b1;8.33</td><td align="left" valign="top" rowspan="1" colspan="1">15.0&#x000b1;7.61</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">16.5&#x000b1;7.68</td><td align="left" valign="top" rowspan="1" colspan="1">18.6&#x000b1;6.18</td><td align="left" valign="top" rowspan="1" colspan="1">15.6&#x000b1;8.97</td><td align="left" valign="top" rowspan="1" colspan="1">14.8&#x000b1;5.53</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rey30<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">12.4&#x000b1;5.05</td><td align="left" valign="top" rowspan="1" colspan="1">12.8&#x000b1;3.78</td><td align="left" valign="top" rowspan="1" colspan="1">12.8&#x000b1;6.12</td><td align="left" valign="top" rowspan="1" colspan="1">13.5&#x000b1;4.91</td><td align="left" valign="top" rowspan="5" colspan="1">2.87 (0.70 to 5.04)<break/><italic>P</italic>=0.01<xref ref-type="table-fn" rid="tfn4-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="5" colspan="1">1.37 (&#x02212;0.89 to 3.63)<break/><italic>P</italic>=0.24</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Draw from memory at 30 minutes</td><td align="left" valign="top" rowspan="1" colspan="1">3 months</td><td align="left" valign="top" rowspan="1" colspan="1">16.6&#x000b1;7.45</td><td align="left" valign="top" rowspan="1" colspan="1">16.2&#x000b1;5.75</td><td align="left" valign="top" rowspan="1" colspan="1">12.5&#x000b1;5.40</td><td align="left" valign="top" rowspan="1" colspan="1">12.8&#x000b1;4.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6 months</td><td align="left" valign="top" rowspan="1" colspan="1">15.7&#x000b1;8.21</td><td align="left" valign="top" rowspan="1" colspan="1">17.3&#x000b1;5.59</td><td align="left" valign="top" rowspan="1" colspan="1">14.0&#x000b1;8.95</td><td align="left" valign="top" rowspan="1" colspan="1">16.1&#x000b1;6.12</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#x02003;Max =36</td><td align="left" valign="top" rowspan="1" colspan="1">9 months</td><td align="left" valign="top" rowspan="1" colspan="1">15.2&#x000b1;8.67</td><td align="left" valign="top" rowspan="1" colspan="1">18.0&#x000b1;5.00</td><td align="left" valign="top" rowspan="1" colspan="1">15.5&#x000b1;7.73</td><td align="left" valign="top" rowspan="1" colspan="1">15.1&#x000b1;6.81</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 months</td><td align="left" valign="top" rowspan="1" colspan="1">16.8&#x000b1;7.71</td><td align="left" valign="top" rowspan="1" colspan="1">19.2&#x000b1;6.57</td><td align="left" valign="top" rowspan="1" colspan="1">16.4&#x000b1;8.75</td><td align="left" valign="top" rowspan="1" colspan="1">15.0&#x000b1;7.23</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-cia-9-1327"><p><bold>Notes:</bold> Test results are means &#x000b1; standard deviation. Treatment effects are shown with 95% confidence intervals in parentheses.</p></fn><fn id="tfn4-cia-9-1327"><label>*</label><p>Statistically significant result, <italic>P</italic>&#x0003c;0.05.</p></fn><fn id="tfn5-cia-9-1327"><p><bold>Abbreviations:</bold> Max, maximum score; Rey0, baseline Rey-Osterrieth Complex Figure Test; Rey5, 5-minute recall trial of the Rey-Osterrieth Complex Figure Test; Rey30, 30-minute recall trial of the Rey-Osterrieth Complex Figure Test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-cia-9-1327" position="float"><label>Table 3</label><caption><p>Baseline correlation analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Cognitive or psychological test</th><th align="left" valign="top" rowspan="1" colspan="1">Age</th><th align="left" valign="top" rowspan="1" colspan="1">Testosterone</th><th align="left" valign="top" rowspan="1" colspan="1">BioT</th><th align="left" valign="top" rowspan="1" colspan="1">DHT</th><th align="left" valign="top" rowspan="1" colspan="1">E2</th><th align="left" valign="top" rowspan="1" colspan="1">BioE2</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Depression<xref rid="b16-cia-9-1327" ref-type="bibr">16</xref>,<xref rid="b17-cia-9-1327" ref-type="bibr">17</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.31 (<italic>P</italic>=0.014)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.22 (<italic>P</italic>=0.090)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.23 (<italic>P</italic>=0.07)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (<italic>P</italic>=0.18)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.044 (<italic>P</italic>=0.74)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.068 (<italic>P</italic>=0.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trail Making Test A<xref rid="b18-cia-9-1327" ref-type="bibr">18</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.45 (<italic>P</italic>&#x0003c;0.001)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.22 (<italic>P</italic>=0.082)</td><td align="left" valign="top" rowspan="1" colspan="1">0.034 (<italic>P</italic>=0.79)</td><td align="left" valign="top" rowspan="1" colspan="1">0.25 (<italic>P</italic>=0.054)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.15 (<italic>P</italic>=0.25)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (<italic>P</italic>=0.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trail Making Test B<xref rid="b18-cia-9-1327" ref-type="bibr">18</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.35 (<italic>P</italic>=0.006)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.074 (<italic>P</italic>=0.575)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.10 (<italic>P</italic>=0.41)</td><td align="left" valign="top" rowspan="1" colspan="1">0.15 (<italic>P</italic>=0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.09 (<italic>P</italic>=0.45)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (<italic>P</italic>=0.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Life Satisfaction Index A<xref rid="b15-cia-9-1327" ref-type="bibr">15</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.35 (<italic>P</italic>=0.006)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.10 (<italic>P</italic>=0.432)</td><td align="left" valign="top" rowspan="1" colspan="1">0.046 (<italic>P</italic>=0.73)</td><td align="left" valign="top" rowspan="1" colspan="1">0.15 (<italic>P</italic>=0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.27 (<italic>P</italic>=0.039)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.26 (<italic>P</italic>=0.050)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Life Satisfaction Index B<xref rid="b15-cia-9-1327" ref-type="bibr">15</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.26 (<italic>P</italic>=0.047)<xref ref-type="table-fn" rid="tfn7-cia-9-1327">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.17 (<italic>P</italic>=0.186)</td><td align="left" valign="top" rowspan="1" colspan="1">0.17 (<italic>P</italic>=0.18)</td><td align="left" valign="top" rowspan="1" colspan="1">0.19 (<italic>P</italic>=0.13)</td><td align="left" valign="top" rowspan="1" colspan="1">0.043 (<italic>P</italic>=0.75)</td><td align="left" valign="top" rowspan="1" colspan="1">0.053 (<italic>P</italic>=0.69)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Benton Judgment of Line Orientation<xref rid="b19-cia-9-1327" ref-type="bibr">19</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (<italic>P</italic>=0.17)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.010 (<italic>P</italic>=0.937)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.20 (<italic>P</italic>=0.12)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.03 (<italic>P</italic>=0.79)</td><td align="left" valign="top" rowspan="1" colspan="1">0.16 (<italic>P</italic>=0.20)</td><td align="left" valign="top" rowspan="1" colspan="1">0.16 (<italic>P</italic>=0.21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rey0<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.011 (<italic>P</italic>=0.93)</td><td align="left" valign="top" rowspan="1" colspan="1">0.11 (<italic>P</italic>=0.421)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.10 (<italic>P</italic>=0.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.12 (<italic>P</italic>=0.35)</td><td align="left" valign="top" rowspan="1" colspan="1">0.02 (<italic>P</italic>=0.84)</td><td align="left" valign="top" rowspan="1" colspan="1">0.066 (<italic>P</italic>=0.62)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rey5<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.029 (<italic>P</italic>=0.83)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.092 (<italic>P</italic>=0.501)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (<italic>P</italic>=0.20)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.034 (<italic>P</italic>=0.80)</td><td align="left" valign="top" rowspan="1" colspan="1">0.072 (<italic>P</italic>=0.59)</td><td align="left" valign="top" rowspan="1" colspan="1">0.10 (<italic>P</italic>=0.44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rey30<xref rid="b20-cia-9-1327" ref-type="bibr">20</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.023 (<italic>P</italic>=0.86)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.059 (<italic>P</italic>=0.668)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.25 (<italic>P</italic>=0.06)</td><td align="left" valign="top" rowspan="1" colspan="1">0.010 (<italic>P</italic>=0.943)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001 (<italic>P</italic>=0.99)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.011 (<italic>P</italic>=0.93)</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-cia-9-1327"><p><bold>Notes:</bold> Values are Pearson correlation coefficients. <italic>P</italic>-values are for two-sided correlation test.</p></fn><fn id="tfn7-cia-9-1327"><label>*</label><p>Statistically significant result, <italic>P</italic>&#x0003c;0.05.</p></fn><fn id="tfn8-cia-9-1327"><p><bold>Abbreviations:</bold> BioE2, bioavailable estradiol; BioT, bioavailable testosterone; DHT, dihydrotestosterone; E2, estradiol; Rey0, baseline Rey-Osterrieth Complex Figure Test; Rey5, 5-minute recall trial of the Rey-Osterrieth Complex Figure Test; Rey30, 30-minute recall trial of the Rey-Osterrieth Complex Figure Test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>